Internal Medicine Clinical Pathological Conference July 18 2008

  • Slides: 19
Download presentation
Internal Medicine Clinical Pathological Conference July 18, 2008

Internal Medicine Clinical Pathological Conference July 18, 2008

Diagnostic Procedure n Right thigh skeletal muscle biopsy

Diagnostic Procedure n Right thigh skeletal muscle biopsy

Further Evaluation: TEST Anti- RNP ab REFERENCE RANGE Negative RF (U/m. L) <15 <10

Further Evaluation: TEST Anti- RNP ab REFERENCE RANGE Negative RF (U/m. L) <15 <10 CCP Ig. G ab <20 24 Anti Jo-1 ab 0 -1 negative >6 Anti SS-A ab Negative Anti SS-B ab Negative Anti Smith ab Negative Anti Scl-70 ab Negative

Further Evaluation: n Thoracentesis • Transudative fluid n AFB sputum negative x 3 n

Further Evaluation: n Thoracentesis • Transudative fluid n AFB sputum negative x 3 n EMG • Sensory and motor neuropathy, but cannot exclude myopathy n Modified Barium Swallow Examination • Moderate dyshphagia with unilateral left pharyngeal weakness

Key Features: n Clinical n • • • Proximal muscle weakness • Arthralgia •

Key Features: n Clinical n • • • Proximal muscle weakness • Arthralgia • Dysphagia • Absence of rash n Radiology • Bilateral interstitial fibrosis • Transudative effusion Laboratory n Elevated creatine kinase Elevated Anti-Jo 1 Elevated ESR, CRP Transaminitis EMG • Neuropathy

Idiopathic Inflammatory Myopathy n Subclassified • Polymyositis • Dermatomyositis • Inclusion body myositis n

Idiopathic Inflammatory Myopathy n Subclassified • Polymyositis • Dermatomyositis • Inclusion body myositis n Histological: endomysial inflammation and activation of the immune response

Idiopathic Inflammatory Myopathy n Epidemiology • Annual incidence: 2 -10 per million • Polymyositis:

Idiopathic Inflammatory Myopathy n Epidemiology • Annual incidence: 2 -10 per million • Polymyositis: n Disease of adult; rare in people younger than 20 years old • Dermatomyositis: n n Two peaks: 5 -10 years old and 50 years old Female to male – 2: 1 • Inclusion body myositis n Older than 50 years of age

Polymyositis/Dermatomyositis n Diagnostic criteria, Bohan and Peter, 1975 1. Symmetrical, proximal muscle weakness 2.

Polymyositis/Dermatomyositis n Diagnostic criteria, Bohan and Peter, 1975 1. Symmetrical, proximal muscle weakness 2. Elevation of serum skeletal muscle enzymes n CK, LDH, AST, ALT, and Aldolase 3. Muscle biopsy with evidence of myositis 4. EMG pattern of myopathy 5. Typical rash of dermatomyositisphotosensitive rash, heliotrope rash, and gottron papules Gottron Papules Heliotrope rash

Polymyositis/ Dermatomyositis n Esophageal involvement (8 -30%), inflammation of cardiac muscle n Interstitial Lung

Polymyositis/ Dermatomyositis n Esophageal involvement (8 -30%), inflammation of cardiac muscle n Interstitial Lung disease (50%) • Nonspecific interstitial pneumonia (NSIP) • Usual interstitial pneumonia (UIP) n Anti-Jo 1 and Anti-Mi 2 • Anti- Jo-1 commonly have Interstitial lung disease • Anti-M 1 have skin findings n Increase cancer risk • 7 -10% of polymyositis • 15 -20% of dermatomyositis

Polymyositis/ Dermatomyositis n Cellular immunity • Polymyositis- Class II HLA antigen DR 3, predominant

Polymyositis/ Dermatomyositis n Cellular immunity • Polymyositis- Class II HLA antigen DR 3, predominant CD 8 T cells • Dermatomyositis- Predominant B cells and CD 4 T cells in inflammatory infiltrates

Inclusion Body Myositis n n n May be asymmetric and involves distal muscles Dysphagia

Inclusion Body Myositis n n n May be asymmetric and involves distal muscles Dysphagia is prominent( 40 -80%) Muscle enzyme is only mildly elevated EMG- Myopathic and Neuropathic Biopsy- mononuclear infiltrates and red-rimmed vacuoles in muscle cells with inclusion bodies Mild response to conventional steroid treatment

Inclusion Body Myositis: Pathogenesis n Engel and Arahata 1984 • Endomysial infiltrates are composed

Inclusion Body Myositis: Pathogenesis n Engel and Arahata 1984 • Endomysial infiltrates are composed of primarily CD 8+ T Cells n Engela and Engel 1988; Orimo 1994; Schmidt 2004 • CD 8+ T Cells surrounds MHC class I myofibers and express perforin n Cupler 1996; Saperstien 1999; Tsuruta 2001; Dalakas 2006 • Association with chronic viral infection

Inclusion Body Myositis: Pathogenesis n Hypothesis- Dalakas 2006 Dalakas, 2006 Disease begins with viral

Inclusion Body Myositis: Pathogenesis n Hypothesis- Dalakas 2006 Dalakas, 2006 Disease begins with viral infection HIV, HTLV-1, Hepatitis C 1. Clonal expansion of CD 8+ T cells and T-cell mediated, MHC class I cytotoxicity via perforin pathway leading to necrosis 2. Cytokines upregulate MHC class I molecules leading to MHC-peptide loading complex and endoplasmic reticulum (ER) stress 3. ER stress leads to activation of transcription factor NFk. B, further stimulating MHC/CD 8 complex and induce a self-sustain inflammatory response

Treatment n Polymyositis/ Dermatomyositis • High dose corticosteroids- respond within 6 weeks • Methotrexate,

Treatment n Polymyositis/ Dermatomyositis • High dose corticosteroids- respond within 6 weeks • Methotrexate, cyclosporine, and IVIG n Inclusion body myositis • Most immunotherapeutic agents are ineffective n Age appropriate cancer screening

FINAL DIAGNOSIS: Inclusion Body Myositis Dermatomyositis sine dermatitis

FINAL DIAGNOSIS: Inclusion Body Myositis Dermatomyositis sine dermatitis

Pathogenesis of Patient’s disease Viral Infection Clonal expansion of CD 8+ T Cell Complex

Pathogenesis of Patient’s disease Viral Infection Clonal expansion of CD 8+ T Cell Complex with MHC class I Cytotoxicity via perforin pathway causing necorsis B cells and CD 4 T cells in inflammatory infiltrates Cytokine release Endoplasmic reticulum stress and Intracellular peptide loading complex Skeletal muscle inflammation Epidermal and dermal destruction Skeletal muscle inflammation Inclusion Body Myositis Dermatomyositis Interstitial lung disease Cough Recurrent Aspiration Dysphagia Proximal muscle Weakness, myalgia Elevated serum muscle enzymes Rash

Case Follow-up n Patient was started on empiric antibiotics for aspiration pneumonia n Started

Case Follow-up n Patient was started on empiric antibiotics for aspiration pneumonia n Started on prednisone 30 mg bid n Pt transferred to subacute inpatient rehabilitation n CPK=5675, AST=237, ALT=252 after one week of prednisone therapy n Pt with improvement in deltoid strength and proximal muscle strength

Case Follow-up n n n Eventually discharged with outpatient rheumatology follow up Initially, clinical

Case Follow-up n n n Eventually discharged with outpatient rheumatology follow up Initially, clinical symptoms improved and patient was maintained on daily steroid for about 1 year Patient was found to have rising CK, and Azathioprine was added to his regimen Azathioprine did not improve his CK levels, and was switched to Mycophenolate mofetil Patient was electively admitted 2 weeks ago for IVIG as CK levels continue to be elevated

THANK YOU! n Medical Student Discussants Michael Goldman Juan Lado Megan Mcgill Nekee Pandya

THANK YOU! n Medical Student Discussants Michael Goldman Juan Lado Megan Mcgill Nekee Pandya n Moderator: Martin Blaser, MD Faculty Discussant: Peter Izmirly, MD n Radiology Speaker: Dr. David Naidich , MD n Pathology Speaker: David Zagzag, MD n SPECIAL THANKS: Christina Yoon , MD, Harry n Shen, MD and Jean Park, M. D.